UK markets close in 32 minutes
  • FTSE 100

    6,642.63
    -32.84 (-0.49%)
     
  • FTSE 250

    21,283.81
    -152.51 (-0.71%)
     
  • AIM

    1,173.64
    -15.25 (-1.28%)
     
  • GBP/EUR

    1.1619
    +0.0057 (+0.49%)
     
  • GBP/USD

    1.3996
    +0.0043 (+0.31%)
     
  • BTC-GBP

    35,387.13
    -1,161.56 (-3.18%)
     
  • CMC Crypto 200

    994.78
    +7.57 (+0.77%)
     
  • S&P 500

    3,825.24
    +5.52 (+0.14%)
     
  • DOW

    31,304.79
    +34.70 (+0.11%)
     
  • CRUDE OIL

    63.50
    +2.22 (+3.62%)
     
  • GOLD FUTURES

    1,718.40
    +2.60 (+0.15%)
     
  • NIKKEI 225

    28,930.11
    -628.99 (-2.13%)
     
  • HANG SENG

    29,236.79
    -643.63 (-2.15%)
     
  • DAX

    14,051.80
    -28.23 (-0.20%)
     
  • CAC 40

    5,829.37
    -0.69 (-0.01%)
     

IBA–Acquisition of Own Shares

IBA SA
·2-min read

Tab

Tab
Tab
Tab

Immediate Release – February 11th, 2021

Louvain-la-Neuve, Belgium, February 11th, 2021 07:30 pm - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on January 12th, 2021.

Under this program, IBA has requested a financial intermediary to repurchase up to 357.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until May 31st, 2021, effective as from January 13th, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel.

In the framework of this share buyback program, IBA repurchased 17.572 IBA shares on Euronext Brussels in the period from February 5th, 2021 up to and including February 11th, 2021, as follows:

Tab

The total number of shares purchased under this program therefore amounts to 97.560.

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

Contact person
IBA
Christian Matton,
Chief Legal Officer
shareholderrelations@iba-group.com

Attachments